Drugs Can Cut Breast Cancer Risk for Some: Experts
Draft guidelines for doctors reflect findings, but it's hard to know who will benefit most, experts say
By Carina Storrs
MONDAY, April 15 (HealthDay News) -- The drugs tamoxifen and raloxifene (Evista) could reduce the risk of breast cancer among women who are at high risk of developing the disease, a new report confirms.
Along with the report, the U.S. Preventive Services Task Force also issued draft recommendations that reflect those findings, which will be published in the April 16 issue of the Annals of Internal Medicine.
The task force recommendations state that doctors should talk about the potential benefits and harms of taking drugs to prevent breast cancer, a strategy known as chemoprevention, with patients who are at high risk of developing breast cancer.
That guideline is consistent with that of the American College of Obstetricians and Gynecologists and the American Cancer Society, and reflects current clinical practice, the task force said.
"We had a nice set of well-done, large [studies], so we have a lot of confidence in the results to really inform the recommendations," said report author Dr. Heidi Nelson, a research professor of medical informatics and clinical epidemiology at the Oregon Health and Science University in Portland. Nelson and the other report authors are not task force members and were contracted by the panel to analyze and summarize the latest research for the report.
One of the report's key findings was that studies of tamoxifen reported a decrease in breast cancer incidence from 23.5 per 1,000 women in the placebo group to 16.5 per 1,000 among women taking tamoxifen over a five-year period. Nelson and her colleagues arrived at these numbers by analyzing four studies of women who took tamoxifen for about four years and their rates of breast cancer over the following seven to 13 years.
Another advance since the 2002 recommendations is a 2010 study that compared tamoxifen and raloxifene directly. "Tamoxifen is more effective at reducing breast cancer risk, but it has more side effects," Nelson said. In this study, there were five fewer cancers per 1,000 women taking tamoxifen when compared with raloxifene.